7 years ago

Clyz Labs Secures Seed Funding to Advance Cancertain™ Assay

  • Clyz Labs, a Manchester UK-based early-stage cancer diagnostics company, has raised an undisclosed amount of seed funding from Catapult Ventures through the GM&C Life Sciences Fund

  • Clyz Labs is developing the Cancertain™ Assay as a service to select the best drug therapy for personalized cancer treatment

  • The company will use the funds to further optimize and validate the Cancertain™ Assay in patients with lung cancer and to generate much needed evidence in a clinical setting

  • The company is advancing the first clinical trial involving its test, which has already secured all regulatory approvals.

      • ProblemHealthcare

      "A personalized cancer treatment that selects the best drug therapy for an individual patient"

      Solution

      "A 3D cell culture technique-based test that combines information on drug sensitivity and biomarkers to provide a personalized treatment recommendation"

      Covered on